Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FDEP9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,598
Award facts
- Contract value 100% obligated
- $20,598.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $20,598.16 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/mL syringes. The contract is firm fixed-price with no set-aside designation, and the ultimate completion date is February 6, 2026. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, designated as SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The PPV-G GEN V represents a $30.3 billion acquisition strategy through which the Defense Logistics Agency establishes regional prime vendor contracts to supply comprehensive pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial capability as a federal pharmaceutical supplier, with its IDC holding a $499,999,999 ceiling value and an ultimate completion date of December 31, 2036. The company's product portfolio spans branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables, supporting the diverse pharmaceutical requirements of military medical systems globally. As a prime vendor contractor with no identified subcontractors on this award, DMS Pharmaceutical Group operates as a direct supplier to DLA's Medical Supply Chain division, having received numerous delivery orders reflecting consistent performance across multiple therapeutic categories and product lines.
Quick answers
Who was awarded contract SPE2DR26FDEP9?
SPE2DR26FDEP9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26FDEP9 worth?
The government has obligated $20,598 on SPE2DR26FDEP9.
Is contract SPE2DR26FDEP9 an order under another contract?
Yes. SPE2DR26FDEP9 is a delivery order under SPE2DR25D9112, an indefinite delivery contract.
Was contract SPE2DR26FDEP9 competed?
The extent of competition for SPE2DR26FDEP9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award